Journal article · 2026 · Open access
M1 macrophage membrane-engineered PLGA nanoparticles reprogram M2 tumor-associated macrophages to enhance anti-tumor immunity in breast cancer
Journal of Materials Science Materials in Medicine, 37(1) · Published 20 February 2026 · DOI 10.1007/s10856-026-07017-2
In brief
“M1 macrophage membrane-engineered PLGA nanoparticles reprogram M2 tumor-associated macrophages to enhance anti-tumor immunity in breast cancer” is a 2026 journal article by Asal Katebi and 3 co-authors, published in Journal of Materials Science Materials in Medicine. OpenAlex counts 3 citations as of 18 November 2026, which puts it in the top 4% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Journal of Materials Science Materials in Medicine.
- Citations
- 3
- Most cited in
- 2026 (3)
- Field-weighted impact
- 5.19
- References
- 79
- Authors
- 4
Abstract
Nanoparticles (NPs) are used as a suitable delivery system in cancer immunotherapy. Coating NPs with cell membranes can improve their therapeutic efficacy. Tumor-associated macrophages (TAMs) with a dominant phenotype of M2 and anti-inflammatory properties are found within the tumor microenvironment and contribute to tumor progression. Reprogramming TAMs toward a pro-inflammatory M1 phenotype can be a suitable approach to alter the tumor microenvironment and improve treatment outcomes. In this study, we synthesized poly(lactic-co-glycolic acid) (PLGA) NPs loaded with a TLR7/8 agonist (R848) and coated with M1 macrophage cell membranes (CM1), along with a cyclic dinucleotide (CDN) agonist (PLGA-CM1-CDN-R848 NPs), and their ability to reprogram M2-like macrophages was investigated using an in vitro model. PLGA-CM1-CDN-R848 NPs were preferentially taken up by M2-like macrophages and efficiently stimulated the pro-inflammatory cytokines (IL-6, TNF-α, and iNOS) as well as the STING pathway (IFN-β). The reprogrammed macrophages induced apoptosis and cell cycle arrest (G0/G1 and G2/M phases) in 4T1 breast cancer cells. In conclusion, the PLGA-CM1-CDN-R848 NPs formulation represents a promising strategy for breast cancer immunotherapy by targeting M2 TAMs within the TME and reprogramming them toward the M1 phenotype.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Katebi, A., Riazi‐Rad, F., Ahangari, F., & Ajdary, S. (2026). M1 macrophage membrane-engineered PLGA nanoparticles reprogram M2 tumor-associated macrophages to enhance anti-tumor immunity in breast cancer. Journal of Materials Science Materials in Medicine, 37(1). https://doi.org/10.1007/s10856-026-07017-2
MLA 9
Katebi, Asal, et al. “M1 macrophage membrane-engineered PLGA nanoparticles reprogram M2 tumor-associated macrophages to enhance anti-tumor immunity in breast cancer.” Journal of Materials Science Materials in Medicine, vol. 37, no. 1, 2026. https://doi.org/10.1007/s10856-026-07017-2.
Chicago
Katebi, Asal, Farhad Riazi‐Rad, Fatemeh Ahangari, and Soheila Ajdary. 2026. “M1 macrophage membrane-engineered PLGA nanoparticles reprogram M2 tumor-associated macrophages to enhance anti-tumor immunity in breast cancer.” Journal of Materials Science Materials in Medicine 37 (1). https://doi.org/10.1007/s10856-026-07017-2.
Harvard
Katebi, A. et al. (2026) ‘M1 macrophage membrane-engineered PLGA nanoparticles reprogram M2 tumor-associated macrophages to enhance anti-tumor immunity in breast cancer’, Journal of Materials Science Materials in Medicine, 37(1). doi:10.1007/s10856-026-07017-2.
IEEE
A. Katebi, F. Riazi‐Rad, F. Ahangari, and S. Ajdary, “M1 macrophage membrane-engineered PLGA nanoparticles reprogram M2 tumor-associated macrophages to enhance anti-tumor immunity in breast cancer,” Journal of Materials Science Materials in Medicine, vol. 37, no. 1, 2026, doi: 10.1007/s10856-026-07017-2.
BibTeX
@article{katebi2026macrophage,
title = {{M1 macrophage membrane-engineered PLGA nanoparticles reprogram M2 tumor-associated macrophages to enhance anti-tumor immunity in breast cancer}},
author = {Katebi, Asal and Riazi‐Rad, Farhad and Ahangari, Fatemeh and Ajdary, Soheila},
journal = {Journal of Materials Science Materials in Medicine},
year = {2026},
volume = {37},
number = {1},
doi = {10.1007/s10856-026-07017-2},
url = {https://doi.org/10.1007/s10856-026-07017-2}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- tumor-associated macrophages
- M2 macrophage reprogramming
- PLGA nanoparticles
- breast cancer immunotherapy
- R848
- TLR7/8 agonist
- STING pathway
- tumor microenvironment
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Katebi, A., Riazi‐Rad, F., Ahangari, F., & Ajdary, S. (2026). M1 macrophage membrane-engineered PLGA nanoparticles reprogram M2 tumor-associated macrophages to enhance anti-tumor immunity in breast cancer. Journal of Materials Science Materials in Medicine, 37(1). https://doi.org/10.1007/s10856-026-07017-2
How many times has this paper been cited?
3 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal of Materials Science Materials in Medicine: sign in and open the full text from this page.
Who wrote this paper?
Asal Katebi, Farhad Riazi‐Rad, Fatemeh Ahangari, Soheila Ajdary.
What is the DOI of this paper?
10.1007/s10856-026-07017-2, permanently at https://doi.org/10.1007/s10856-026-07017-2. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.